In a systematic review and meta-analysis, Mavrakanas et al. found that SGLT2 inhibitors were associated with a decreased incidence of CKD progression among patients with preexisting CKD (RR: 0.77; 95% CI: 0.68–0.88), compared with placebo. The gene discussed is SLC5A2; the disease is chronic kidney disease.